1. Home
  2. REGN

as 05-09-2025 3:41pm EST

$
-
-
-
.
-
-
-
$
-
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Founded: 1988 Country:
United States
United States
Employees: N/A City: TARRYTOWN
Market Cap: 63.4B IPO Year: 1991
Target Price: $907.39 AVG Volume (30 days): 1.2M
Analyst Decision: Buy Number of Analysts: 23
Dividend Yield:
0.32%
Dividend Payout Frequency: Quarterly
EPS: 39.43 EPS Growth: 16.49
52 Week Low/High: $520.50 - $1211.20 Next Earning Date: 04-29-2025
Revenue: $14,085,700,000 Revenue Growth: 7.52%
Revenue Growth (this year): 2.38% Revenue Growth (next year): 7.65%

REGN Daily Stock ML Predictions

Share on Social Networks: